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occurred after the correction of severe
hyponatraemia in hyperemesis gravidarum
Giovanni Corona1, Luigi Simonetti2, Corinna Giuliani3, Alessandra Sforza1 and Alessandro Peri3*Abstract
Background: Osmotic demyelination syndrome (ODS) may be observed as a result of a rapid change in serum
osmolarity, such as that induced by an overly rapid correction of serum sodium levels in hyponatraemic patients.
Case presentation: We describe the case of a 21-year-old woman who was hospitalized at week 10 of
gestation because of severe hyperemesis. At admission the patient appeared restless and confused and severe
hyponatraemia (serum sodium 107 mmol/L) and hypokalemia (serum potassium 1.1 mmol/L) were detected.
Active and simultaneous correction of these imbalances led to an overly rapid increase of serum sodium levels
(17 mmol/L in the first 24 hours). Isotonic saline solution was stopped and replaced by 5% dextrose solution
infusion. However, the neurological alterations worsened and the radiological features were consistent with the
diagnosis of extra-pontine ODS. Steroids were administered intravenously with progressive improvement of
biochemical and clinical abnormalities. At the time of discharge, 20 days later, the patient was able to walk and
eat autonomously with only minimal external support.
Conclusions: This report illustrates an unusual case of ODS, occurred after an excessive rate of correction of
hyponatraemia obtained with isotonic saline infusion. Hypokaliemia and its active correction very likely played a
crucial role in facilitating the onset of ODS. This interesting aspect will be explained in detail in the article. A more
cautious and thoughtful correction of electrolyte alterations, would have probably prevented the onset of ODS in
this patient. Physicians should be aware of the possibly fatal consequences that an exceedingly rapid change of
serum osmolarity may have and should strictly follow the known safety measures in order to prevent it to occur.
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Osmotic demyelination syndrome (ODS) is an uncom-
mon disorder, characterized by non-inflammatory de-
myelination involving the pons and other areas of the
central nervous system, which may occur for instance as
a consequence of an overly rapid correction of hypona-
traemia [1]. Here we report a case of ODS occurred after
correction of hyponatraemia with isotonic saline solu-
tion in a pregnant woman with hyperemesis gravidarum
and concomitant other electrolyte disorders, which are
additional risk factors for the development of this syn-
drome. Some criticisms in the management of the patient,* Correspondence: alessandro.peri@unifi.it
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unless otherwise stated.which undoubtedly eased the occurrence of ODS, will be
highlighted.
Case presentation
Hyperemesis gravidarum is a condition characterized by
severe vomiting resulting in dehydration, fluid electrolyte
imbalance and weight loss [2]. We report the case of a 21-
year-old woman who was hospitalized at week 10 of gesta-
tion due to severe hyperemesis. The condition appeared at
week 4 of pregnancy and caused her weight to drop from
51 kg to 46 kg. The day of admission to the hospital she
became restless and confused. Clinical examination per-
formed in the emergency room revealed the presence of
mild dehydration (dry mouth and skin) with normal blood
pressure, increased heart rate and slightly reduced breath
frequency (Table 1). Biochemical assessment performed atLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinical and biochemical features of the patient
Clinical data
Weight (kg) 46
Height (cm) 160
BMI (Kg/m2) 17.9
SBP (mmHg) 120
DBP (mmHg) 60
HR (bpm) 120
RF (bpm) 10
Laboratory parameters
Serum data Value Normal range
Glycaemia (mmol/L) 4.17 (3.3-6.5)
Na+ (mmol/L) 107 (135-146)
K+ (mmol/L) 1.1 (3.5-5.0)
Ca++ (mmol/L) 2.5 (2.18-2.58)
Mg++ (mmol/L) 0.90 (1.02-1.84)
Phosphate (mmol/L) 0.41 (0.48-1.45)
Creatinine (μmol/L) 36.24 (50-90)
Urea (mmol/L) 1.83 (2.5-8)
Total protein (g/L) 52 (60-80)
Albumin (g/L) 30 (35-50)
Prealbumin (mg/L) 127 (200-400)
Osmolarity (mmol/kg) 254 (275-295)
Retinol binding protein (mg/dl) 1.33 (1.55-4.59)
TSH (mlU/L) 0.01 (0.4-5.0)
fT3 (pmol/L) 7.06 (3.5-6.5)
fT4 (pmol/L) 28.31 (9-21.80)
ACTH (pmol/L) 2.26 (1.3-16.7)
Cortisol (nmol/L) 606.98 (110-607)
Urinary data
Na+ (mmol/L) 3
K+ (mmol/L) 2
Osmolarity (mmol/kg) 418 (500-1500)
Hemogasanalysis data
pH 7.65
pO2 mmHg 69
pCO2 mmHg 58
BE mmol/L 37.4
HCO3
- mmol/L 63.9
AG mmol/L -10
BMI = body mass index, SBP = systolic blood pressure, DBR = diastolic blood
pressure, HR = heart rate, RF = respiratory frequence, bpm = beats per minute,
BE = base excess, AG = anion gap.
Corona et al. BMC Endocrine Disorders 2014, 14:34 Page 2 of 7
http://www.biomedcentral.com/1472-6823/14/34admission revealed severe hyponatraemia (107 mmol/L)
and hypokalemia (1.1 mmol/L) (Table 1 and Figure 1) with
secondary metabolic alkalosis and partially compensated
respiratory acidosis (Table 1). Urinary data suggested thepresence of extra-renal loss of Na+ and K+ with appropriate
increase of urinary water and electrolyte retention (Table 1).
The patient was promptly admitted to the intensive care
unit of the hospital and intravenous isotonic NaCl solu-
tion along with K-lactate supplementation was started
(Figure 1). The electrolyte disorder was intensively moni-
tored with blood sample evaluation performed every two
hours. However, during the first six hours after admis-
sion an excessive rate of correction of serum Na+
concentration ([Na+]) occurred (Δ 10 mmol/L). Hence,
isotonic solution was replaced with hypotonic solution
(5% dextrose, Figure 1); K-lactate supplementation was
maintained. However, after 24 hours serum [Na+] was 124
nmol/L (Δ 17 mmol//L) and at 48 hours 128 nmol/L. The
neurological symptoms worsened with the appearance of
hypotonia, tremors and involuntary muscle spasms. Hor-
monal data showed the presence of thyrotoxicosis likely
induced by hCG; serum ACTH and cortisol levels showed
no abnormalities. In addition, laboratory data (e.g. reduced
total proteins, albuminemia, retinol binding protein, cre-
atinine, azotemia) indicated the presence of relatively
recent, important malnutrition (Table 1). Electroenceph-
alogram showed a non-specific slow wave activity consist-
ent with the presence of a metabolic disorder. Magnetic
resonance imaging (MRI) of the brain revealed, despite a
normal pons, bilateral increased signal intensity of the
lenticular, claustrum, and caudate cerebral nuclei on axial
T2 weighted images (Figure 2, panel A) and FLAIR images
(Figure 2, panel B). In addition, the Tl weighted images
showed moderate hypointensity in the same nuclei
(Figure 2, panel C). These foci did not enhance with
GDTPA. The clinical and radiological picture was consid-
ered to be consistent with extra-pontine ODS associated
with an overly rapid correction of hyponatraemia, which
was caused by hyperemesis gravidarum At that point,
intravenous steroid infusion and enteral nutrition support
were started with slow improvement of biochemical and
clinical abnormalities. The gynecological examination and
ultrasound fetal monitoring revealed no alterations and
were in agreement with the gestational age. The patient
and her husband were informed on the possible fetal
neurological risks and decided to continue the pregnancy.
At the time of discharge, 20 days later, the patient was able
to walk and eat autonomously with only minimal external
support; serum electrolytes and nutritional parameters
were normal. The patient delivered a healthy male at
36 weeks of gestation (caesarean section). At 4 months
of age the child is apparently healthy. Unfortunately, only
a mild improvement of the neurological alterations of the
mother has been obtained despite physical therapy.
The case presented here describes a condition of ODS
associated with overly rapid correction of serum [Na+]
in a patient with severe hyponatraemia. ODS was first
described in 1959 in a series of alcoholic and malnourished
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Figure 1 Serum [Na+] and [K+] progression during active treatment for the correction of severe hyponatraemia and hypokalemia in
the patient.
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palsy. Post-mortem assessment revealed the presence of a
demyelinative lesion within the central pons [3]. Its rela-
tionship with electrolyte disorders was not apparent, be-
cause routine measurement of serum electrolytes was not
available at that time. A link between ODS and overly rapid
correction of hyponatraemia was established only in the
mid-1970s [4]. ODS is recognized as a rather rare disease,
although the exact frequency with which occurs is not
known. The largest autopsy series indicated a prevalence of
0.25-0.5% in the general population with a peak incidence
in males aged 30 to 60 years [1]. From a pathological point
of view, ODS is characterized by loss of myelin sheath,
whereas axons and neurons are relatively spared [5]. Trad-
itionally, ODS has been associated with rapid correction of
hyponatraemia; however, a number of different conditions
have been reported in association with the development of
this syndrome, independent of serum [Na+] alterations.
The most common predisposing condition is chronic alco-
holism, which was not present in our case [6]. Many pa-
tients developed ODS during the terminal stage of binge
drinking; however, a few case reports of ODS after alcohol
withdrawal have been reported [7]. In these instances, the
osmotic change due to a decreased intake of food or water
that occurs during binge drinking or alcohol withdrawal
may be the cause of ODS development.
ODS has been described in patients after liver trans-
plant, after treatment for hyperammonemic disease orwith dialysis disequilibrium syndrome. This syndrome is
characterized by the occurrence of neurological signs
and symptoms attributed to cerebral edema during or
following shortly after intermittent hemodialysis and is
associated particularly with “aggressive” (high solute re-
moval) dialysis [8,9]. The occurrence of ODS has been
also associated with hyperglycemia or with the correc-
tion of hyperglycemia [10,11]. Severely burned patients
are especially susceptible to ODS, which is tightly associ-
ated with serum hyperosmolality resulting from hypergly-
cemia, azotemia and/or hypernatraemia in these patients
[12]. In pregnant women, ODS may occur following rapid
correction of hyponatraemia, which may be observed in
hyperemesis gravidarum [2], as in the case described here.
Furthermore, several cases of ODS in women with post-
partum hypernatraemia have been described in India [13].
The authors suggested that a possible cause of hyper-
natraemia in these patients might be the presence of
gestational diabetes insipidus together with the habit to
restrict fluid intake during puerperal state in some re-
gions of India.
Overall, these findings strongly suggest that any change
in brain cellular volume as the result of a rapid change in
serum osmolarity may cause an injury to myelin sheats. In
chronic, but not in acute, hypoosmolar states brain cells
adapt by decreasing their intracellular solute content.
Thus, the risk to develop ODS is substantially associated
with chronic hyponatraemia. Noticeably, glial cells have
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C
Figure 2 MRI features. Signal intensity of the lenticular, claustrum, and caudate cerebral nuclei on axial T2 weighted images (A), FLAIR images
(B) and Tl weighted images (C).
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not neurons, swell after hypotonic stress, thus suggest-
ing the existence of glia-specific water pores (i.e. aqua-
porin 1 and 4) [14]. Brain adaptation to cellular swelling
requires 24-48 hours and is driven by glial cells, which
expel solutes followed by water. This is an energy-
dependent phenomenon and requires the activity of the
Na+-K+-ATPase pump. If a rapid correction of a hypoos-
molar state then occurs, glial cells start to increase the
production of organic osmolites and the intracellular ion
content, in order to reverse the previous modification and
regulate cellular volume [15]. However, the synthesis of
organic osmolites, as well as the up-regulation of ion
pumps, require time and causes energy deprivation. Thus,
if an overly rapid correction of a hypotonic state occurs,
the cells may not be able to effectively respond to osmotic
changes and water moves into the extra-cellular space
[15]. Consequently, the resulting shrinkage of glial cells
may cause axonal shear damage. Oligodendrocyteapoptosis may also be induced [15], which may lead to
disruption of the blood-brain barrier. The latter may cause
inflammatory demyelination and further oligodendrocyte
damage [15,16].
Besides serum sodium imbalance, other electrolyte al-
terations, such as hypophosphataemia and hypokalemia,
which were also present in our case, have been associated
with the development of ODS. Acute hypophosphataemia
is a recognized complication of refeeding syndrome when
mineral supplementation is inadequate. The phosphate
depletion causes failure to convert ADP into ATP leading
to an intracellular energy crisis [17], which likely causes
altered function of the Na+-K+-ATPase pump and conse-
quently brain cells dysfunction. In addition, because phos-
pholipids are a major component of myelin, phosphate
depletion may disrupt myelin integrity [18]. With regard
to hypokalemia, the mechanism leading to an increased
risk of ODS is not completely clear. Nevertheless, different
possibilities have been proposed [1]. For instance, a
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present, which was the situation of the case reported here,
its correction rate may be increased by the simultaneous
correction of hypokalemia. This statement is based on the
observation that the Na+-K+-ATPase pump on the cell
membrane expels Na+ as K+ enter the cell to replenish de-
pleted intracellular stores. The consequence is a more
rapid rate of correction of serum [Na+], which increases
the risk to develop ODS. The simultaneous correction of
hypokaliemia may has been therefore an important trigger
for the overly rapid correction of hyponatraemia observed
in this case and for the further raise occurred also after
the replacement of saline infusion with 5% dextrose solu-
tion. With this critical aspect in mind, admittedly a more
cautious correction of hyponatraemia and a more appro-
priate intervention aiming to re-lower serum [Na+], i.e.
using also desmopressin, would have likely prevent the
onset of ODS.
Clinically, ODS may present with a variety of neuro-
logical signs and symptoms, depending on the severity
of the involvement and on the affected areas. In about
50% of cases isolated central pontine myelinolysis (CPM)
occurs, whereas the remaining cases are more or less
equally divided into isolated extra-pontine myelinolysis
(EPM) or a combination of CPM and EPM, with a slight
prevalence of the latter condition [19]. A number of sites
may be involved, besides the pons, and among the most
frequently affected sites there are the cerebellum, lateral
geniculate bodies, external and extreme capsule and
hippocampus. A complete list of affected areas is shown
in Table 2 and includes caudate and lenticular nuclei
and the claustrum, three extra-pontine areas in which
lesions were observed in the patient described here. In
CPM usually the clinical presentation includes dysarthria
and dysphagia secondary to the involvement of cortico-
bulbar fibres, flaccid quadriparesis followed by spasti-
city, due to corticospinal tract involvement, oculomotor
abnormalities. Changes in mental status and conscious
level may occur. In EPM a variety of behavioral changesTable 2 Cerebral areas involved in CPM and EPM
Common Rare
Pons Internal capsula
Cerebellum Claustrum
Lateral geniculate body Midbrain
Extreme capsule Mammillary body
External capsule Medulla oblongata
Putamen Internal medullary lamella
Hippocampus
Thalamus
Cerebral cortex/subcortex
Caudate nucleusand movement disorders may be present. These include
parkinsonism, dystonia, mutism, catatonia and dyspho-
nia [19]. Usually, these alterations develop several days
after the correction of the hypoosmolar condition, al-
though encephalopathy may be already present after a
few hours [6]. A possible case of ODS with peripheral
nervous system involvement after hyponatraemia correc-
tion, causing bilateral and symmetrical motor demyelinat-
ing polyneuropathy in the lower and upper extremities in
association with central nervous system involvement,
has been described [20]. However, admittedly systematic
neurophysiological screening of an adequate series of
patients with ODS would be required in order to con-
firm this hypothesis.
The diagnosis of ODS is based initially on clinical sus-
picion. Any patient with new onset neurological signs/
symptoms and with a recent rise in serum [Na+] and/or
with associated risk factors for ODS, as mentioned pre-
viously, should be considered possibly affected by ODS.
Clinical findings have to be correlated with radiological
assessment. MRI of the brain is the gold standard im-
aging technique to reveal ODS lesions. These include
hypointense T1-weighted lesions and hyperintense le-
sions demonstrated on T2-weighted and FLAIR images.
The lesions are non-contrast enhancing. All these features
are in agreement with the findings we observed in our
case. The time of appearance may vary and may be de-
layed; sometimes lesions appeared at MRI even 2 weeks
after the onset of clinical alterations [21]. Typically, radio-
logical findings do not improve over time, despite a
complete clinical recovery [22].
The prognosis of ODS has been considered very nega-
tive for a long time and before the availability of modern
imaging techniques usually ODS was a post-mortem
diagnosis. The first in-life diagnosis was formulated only
10 years after the first description of ODS. In recent years,
the mortality rate has markedly decreased and patients
with complete recovery are not rarely observed. In a series
of 44 German patients with ODS, for instance, only 6%
died during the observation period and 40% recovered
without apparent neurological alterations [22].
With regard to treatment, the best therapy for ODS
would be…to prevent it to occur! Particular attention
should be dedicated to patients presenting conditions
known to be associated with a higher risk to develop this
condition. As a general rule, the rate of correction should
not exceed 12 mmol/L within 24 hours, or 18 mmol/L
within 48 hours. These limits should be reduced to
8 mmol/L within 24 hours and 12 mmol/L within 48 hours
in patients with chronic hyponatraemia and associated risk
factors for developing ODS, which include very low serum
[Na+], hypokalemia, malnutrition and hypophosphataemia,
which were present in the case reported here [23,24]. In
terms of more prudential approaches, it has also to be
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panel recommendations” on hyponatraemia, that a 4-
6 mmol/L increase in serum [Na+] is already sufficient to
reverse the most serious manifestations of acute hypona-
traemia [24]. In this patient simultaneous correction of se-
vere hyponatraemia and hypokalemia resulted in a 24-hour
increase of serum [Na+] of 17 mmol/L. In such instances,
uncertainty regarding the optimal approach still exists,
mostly due to the lack of trials in human subjects. Re-
induction of hyponatraemia by using desmopressin, intra-
venous 5% dextrose solution or a combination of both is
usually unnecessary in acute hyponatraemia, may be op-
tional in patients with low to moderate risk of ODS, but
it is definitively recommended in patients at high risk of
ODS [24]. The occasional use of corticosteroids has
been reported in the literature. A possible favorable ef-
fect of corticosteroids in ODS, which were administered
to the patient described here, is to stabilize the blood-
brain barrier [1], although there is no definitive evidence
of a clear benefit in humans. Urea or myoinositol have
been used in animal studies, aiming to restore intracel-
lular organic osmolites, thus protecting from cellular
dehydration [1]. Prompt treatment with minocycline, a
selective and potent inhibitor of microglial activation,
has been proven to be effective in counteracting the ac-
cumulation and the pro-inflammatory activity of micro-
glia, which usually occurs in demyelinative lesions in ODS
[25]. Plasmapheresis has been used in a few patients and
its beneficial effect has been possibly related to the reduc-
tion of inflammatory mediators and consequently to a
protective effect on the blood-brain barrier [1]. Similarly,
a few cases of successful treatment with intravenous im-
munoglobulin have been reported [26]. The mechanism of
action of immunoglobulin in reversing the effects of de-
myelination remains to be elucidated, but it includes the
possible reduction of myelinotoxic substances and the
induction of remyelination [27]. Dopaminergic mole-
cules appear helpful in improving neurological alter-
ations once ODS is fully established [5]. Besides
pharmacological treatment, the approach to ODS in-
cludes physical therapy, similarly to other neurological
disorders.
Conclusions
We reported here a case of ODS occurred in a pregnant
woman with hyperemesis gravidarum after an overly rapid
correction of low serum [Na+] in the presence of several
concomitant risk factors. The overly rapid increase of
serum sodium may has been likely caused by the simultan-
eous correction of severe hypokalemia and it might have
been prevented by a more cautious and thoughtful man-
agement of the patient. This case may very well be consid-
ered as an appropriate example to reinforce warning
among physicians about the care that should be taken in aclinical setting, in order to prevent rapid changes in serum
osmolarity, which may lead to dramatic and sometimes
irreversible consequences.
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